These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation. Benko LB Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517 [No Abstract] [Full Text] [Related]
6. Vioxx may go back on sale after scraping past FDA panel. Wadman M Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304 [No Abstract] [Full Text] [Related]
7. Make or break time in Vioxx drama. Nature; 2006 Mar; 440(7082):277. PubMed ID: 16541045 [No Abstract] [Full Text] [Related]
8. Merck disguised "marketing publication" as medical journal to help promote Vioxx, court hears. Moynihan R BMJ; 2009 Apr; 338():b1714. PubMed ID: 19401326 [No Abstract] [Full Text] [Related]
9. Merck defends Vioxx in court, as publisher apologises for fake journal. Moynihan R BMJ; 2009 May; 338():b1914. PubMed ID: 19433504 [No Abstract] [Full Text] [Related]
10. [Cyclooxygenase inhibitors: a never ending story?]. Macrì R; Manfredi C G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790 [No Abstract] [Full Text] [Related]
11. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? Rahme E; Hunsche E; Toubouti Y; Chabot I Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408 [TBL] [Abstract][Full Text] [Related]
12. AstraZeneca pays $520m fine for off label marketing. Tanne JH BMJ; 2010 Apr; 340():c2380. PubMed ID: 20430836 [No Abstract] [Full Text] [Related]
13. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. Kmietowicz Z BMJ; 2009 Jan; 338():b217. PubMed ID: 19155260 [No Abstract] [Full Text] [Related]